Abstract
Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.
| Original language | English |
|---|---|
| Pages (from-to) | 1189-1192 |
| Number of pages | 4 |
| Journal | International Journal of Oncology |
| Volume | 6 |
| Issue number | 6 |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- IL-10
- Monoclonal component
- Monoclonal gammopathy of uncertain significance
- Multiple myeloma
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Serum interleukin-10 levels in patients affected with multiple myeloma : Correlation with the monoclonal component and disease progression. / Ameglio, F.; Alvino, S.; Trento, E.; Marcucci, M.; Pimpinelli, F.; Tong, A. W.; Gandolfo, G. M.; Greco, C.
In: International Journal of Oncology, Vol. 6, No. 6, 1995, p. 1189-1192.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum interleukin-10 levels in patients affected with multiple myeloma
T2 - Correlation with the monoclonal component and disease progression
AU - Ameglio, F.
AU - Alvino, S.
AU - Trento, E.
AU - Marcucci, M.
AU - Pimpinelli, F.
AU - Tong, A. W.
AU - Gandolfo, G. M.
AU - Greco, C.
PY - 1995
Y1 - 1995
N2 - Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.
AB - Using a commercially available, competitive ELISA kit based on a polyclonal anti-interleukin-10 antibody, serum interleukin-10 (IL-10) levels were quantified in samples of different groups of patients: 20 healthy controls (CTR), 11 monoclonal gammopathies of uncertain significance (MGUS), 17 multiple myelomas (MM), 10 cancer patients (CANCER), 13 cancer patients + MGUS (MGUS-CA) and 7 MGUS patients after surgical removal of concomitant cancer (MGUS-SRCC). Results show significant differences of both the median levels of IL-10 and the monoclonal component (MC) in CTR, MGUS and MM (patients with increasing concentrations in the mentioned order). The IL-10 levels found in the three groups of cancer patients showed serum levels higher than those observed in the controls. Moreover, the surgical cancer removal was related to an IL-10 decrease. A highly significant correlation between serum IL-10 levels and the corresponding MC was also found in the MM-bearing patients and to a lesser extent, in MGUS patients, indicating that serum IL-10 is parallel to the amount of the activated clone causing the monoclonal gammopathy. Since human myeloma lines, cultured in vitro may release significant amounts of IL-10, the data presented support the hypothesis that serum IL-10, measured in myelomatous patients may, at least in part, derive from the activated clone causing the monoclonal gammopathy.
KW - IL-10
KW - Monoclonal component
KW - Monoclonal gammopathy of uncertain significance
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=0029054223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029054223&partnerID=8YFLogxK
M3 - Article
VL - 6
SP - 1189
EP - 1192
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 6
ER -